The American Diabetes Association’s (ADA) 79th Scientific Sessions is almost here! From June 7-11, in San Francisco, CA, scientists and healthcare professionals will gather at one of the largest conferences of diabetes researchers in the world. JDRF researchers and JDRF-funded scientists will also be there to hear first-hand and present new study results that will improve outcomes for people (T1D). Read what’s happening at the ADA Scientific Sessions below.
ADA’s 79th Scientific Sessions
- The Scientific Sessions is one of the largest gatherings of diabetes researchers in the world, where scientists and healthcare professionals share and learn about new diabetes advances with top experts. Approximately 16,000 people are attending.
- JDRF-supported research has been highlighted at this annual event since JDRF started funding research, showcasing new breakthroughs and therapies for people with T1D. This year, researchers will present 75+ studies—with JDRF-funding at present or in the past—encompassing breakthrough clinical trials and significant research studies that are paving the way to novel and emerging treatments for T1D.
- JDRF-funded researchers will outline new advances like:
- Artificial Pancreas: What are the new generation insulins for post-meal blood-sugar control?
- Beta Cell Regeneration: How close are we to the regeneration of insulin-producing beta cells?
- Beta Cell Replacement: How can we make stem cells more like beta cells?
- Complications: What are the genetics around T1D complications?
- Glucose Control: Continuous Glucose Monitoring (CGM) in children—are we there yet?
- Immunotherapy: What is the role of other immune cells, like B cells, in T1D?
- Prevention: Are we on the right path for T1D screening, or is there another way to identify T1D risk?
To read about the conference, go to the ADA Scientific Sessions here.